alexa Web Based Statistical Approaches For Risk Monitoring Of Sponsor Clinical Development Programs | 13815
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Pharmaceutical Regulatory Affairs

Nicole C. Close and Tyson A. Bellamy
Accepted Abstracts: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689.S1.012
Abstract
At EmpiriStat we consider monitoring both a process and implementation of statistical reporting and people ?on the ground? delivered through a risk-based prioritization approach. Many pharmaceutical companies (and often led that way to think by CROs) have interpreted FDA?s guidance that they need 100% auditing by monitors every 6-8 weeks during their study. This is completely not true, and EmpiriStat was pleased to see the release of FDA?s Draft Guidance ?Guidance for Industry Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring? released in August 2011, in which this thought was disputed. EmpiriStat works with the Sponsor on a tailored approach for their particular clinical development program, their sites and trials based on identified and perceived risks. We know and understand the FDA?s current risk based approach for monitoring of sites and sponsors upon their NDA submission, and have used this knowledge as well as our statistical prowess, for creating and implementing risk based approaches during the Sponsor?s IND phase of trial implementation. We know that no one single approach to monitoring is appropriate or necessary for every clinical trial. But we work with each Sponsor and design a statistical monitoring plan that is tailored to the specific human subject protection and data integrity risks of the trial. To provide an integrated monitoring plan and to track metrics across all of the Sponsor?s study, we automate those processes through a webbased system. Through a mix of statistical processes and integrated technology, regulatory GCP compliance can be easily tracked on a Sponsor level, therapeutic level, site level and even a detailed investigator level. Our approach to risk based prioritization monitoring is based on principles of statistics, statistical modeling, good data management, site management and training, and clinical monitoring. We identify the critical data and processes that should be monitored based on the study protocol, knowledge and information about the site, and risk assessment; all adhering to the new guidance from the FDA. This information deals with the complexity of the protocol procedures, the study design, types of study endpoints, the study population, where the study is taking place, the site and its staff (experience, previous studies, competing studies), safety parameters, how the data are being collected and stored, as well as how much data are being collected. Our riskbased approach saves several hundreds of thousands of dollars per study for our clients and potentially could save millions across the clinical development program.
Biography
Nicole C. Close is a clinical trialist, epidemiologist and Biostatistician. As a Board Member of the Society for Clinical Trials (SCT) and a member of the Regulatory Sub-committee of the International Society for Clinical Biostatistics, She is a leader in her field with over 17 years of experience. She is the Lead Statistician contractor for the US Food and Drug Administration?s (FDA) ?Development of Advanced Engineering Methods for Risk-Based Prioritization for Clinical Development and Pharmacovigilance Inspections Project.? On this project she works with the Directors of each FDA Division for identifying the key clinical elements from all Sponsor drug and therapeutic applications filed under IND and NDA status. She has been the Lead Statistician on over 23 open INDs at a previous place of employment with the Department of Defense (USAMRMC) and has provided regulatory strategy and the statistical summaries (integrated summary of safety and integrated summary of efficacy) for multiple NDA submissions to the FDA for various clients. She has also been called to be a statistical reviewer for the NHLBI on Coordinating Center Contract reviews, and a six time statistical panel reviewer for the Department of Defense?s (DoD) Congressionally Directed Medical Research Programs (CDMRP) in wound care (diabetes related issues), Rehabilitation medicine, and Post Traumatic Stress Disorder and Traumatic Brain Injury, reading and evaluating over 265 research applications and providing detailed statistical reviews via written and oral communication on these panels.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected].com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7